Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
Bruce Grasberger(Johnson & Johnson (United States)), Roger Bone(Johnson & Johnson (United States)), Jennifer Lattanze(Johnson & Johnson (United States)), Holly K. Koblish(Wilmington University), Carl L. Manthey(Springhouse), Diane Maguire(Johnson & Johnson (United States)), Maxwell D. Cummings(Johnson & Johnson (United States)), Louis V. LaFrance(Johnson & Johnson (United States)), Anna C. Maroney(AbbVie (United States)), Raul R. Calvo(Johnson & Johnson (United States)), Kannan Ramachandren(Johnson & Johnson (United States)), Ingrid C. Deckman(Johnson & Johnson (United States)), Michael W. Pantoliano, Christopher J. Molloy(Johnson & Johnson (United States)), Eugene C. Petrella(Georgetown University), Tianbao Lu(Johnson & Johnson (United States)), Theodore E. Carver(Johnson & Johnson (United States)), Bruce E. Tomczuk(Johnson & Johnson (United States)), Karen L. Milkiewicz(Johnson & Johnson (United States)), Carsten J. Schubert(Johnson & Johnson (United States)), Marie Zhang(Johnson & Johnson (United States)), Daniel J. Parks(Johnson & Johnson (United States)), Carol F. Franks(Johnson & Johnson (United States)), Gwendolyn R. Bylebyl(Johnson & Johnson (United States)), Shuyuan Zhao(Johnson & Johnson (United States)), John Spurlino
Cited by 430
Related Papers
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Reproducing human and cross-species drug toxicities using a Liver-Chip
|Science Translational Medicine|2019|478
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
|ACS Medicinal Chemistry Letters|2012|377